chufangao/CTO huggingface dataset:
Clinical trial NCT04616079: Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of REGN6490 in Healthy Volunteers
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 57.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-11-19
Primary completion date: 2021-06-01
Completion date: 2021-06-01
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
IPD access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (eg, FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Clinical trial NCT03115151: Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery
Official title: A Comparison of Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery: A Prospective Randomized Study
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The surgical team has difficulty to find level 1 and 2 fusions for the study.
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-08
Primary completion date: 2022-08-18
Completion date: 2023-04-04
Plan to share individual participant data: NO
Clinical trial NCT03860155: Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure
Official title: An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-ACLF for the Treatment of Acute-on-Chronic Liver Failure (ACLF)
Sponsor: RHEACELL GmbH & Co. KG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Very slow recruitment of patients and the current COVID-19 pandemic situation.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-22
Primary completion date: 2021-03-26
Completion date: 2021-03-26
Plan to share individual participant data: NO
Clinical trial NCT03602872: Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis
Official title: Phase I, Open Label Study to Assess the Safety and Tolerance of a Single Intraarticular Dose of STEMEDICA's Human Allogeneic Bone Marrow Derived Mesenchymal Stem Cells, in Subjects With Knee Osteoarthritis.
Sponsor: Clinica Santa Clarita, Mexico (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor to start with different protocol, postponed due to COVID
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-08-31
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Plan to share individual participant data: NO
Clinical trial NCT03948178: Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
Official title: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS: Open-Label Extension for Patients Completing Study 3119002
Acronym: REFALS-ES
Sponsor: Orion Corporation, Orion Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: This was an open label extension for patients completing the REFALS study (3119002; NCT03505021). Study 3119002 showed lack of efficacy of ODM109 so the sponsor decided to terminate this study
Enrollment: 227.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-26
Primary completion date: 2020-11-18
Completion date: 2020-11-18
Baseline population: Intention-to-Treat (ITT) including all randomised subjects was used for the primary evaluation.
Clinical trial NCT04941196: Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition
Official title: A Single Centre, Cross-over, Single Dose, Two Period, Randomized, Open Label Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet With Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition
Acronym: BE
Sponsor: University of Karachi (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-16
Primary completion date: 2020-10-26
Completion date: 2020-11-25
Plan to share individual participant data: NO
IPD sharing description: Data can be obtained upon proper request to principal investigator unless the volunteer's confidentiality is not compromised.
Clinical trial NCT03311555: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Official title: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-28
Primary completion date: 2022-12-22
Completion date: 2022-12-22
Clinical trial NCT03740100: Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
Official title: Open-label, Single Arm, Two-stage Study, Evaluating the Efficacy and Safety of Bimiralisib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (HNSCC) Harboring NOTCH1 Loss of Function (LOF) Mutations
Acronym: HNSCC
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The trial was closed because the sponsor became insolvent.
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-25
Primary completion date: 2020-08-05
Completion date: 2020-12-09
Limitations and caveats: The trial was closed early because the sponsor became insolvent.
Plan to share individual participant data: NO
Clinical trial NCT03497988: Intranasal Oxytocin and Food Intake in Obese Adolescents
Official title: Effect of a Single Dose of Intranasal Oxytocin on Food Intake in Obese Adolescents
Sponsor: Children's Hospital of Philadelphia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Grant proposal not funded, study has been withdrawn with IRB
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-30
Primary completion date: 2020-06-30
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT03672292: Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Official title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Acronym: SCYNERGIA
Sponsor: Scynexis, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment took longer than anticipated (slow enrollment during COVID).
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-22
Primary completion date: 2023-03-27
Completion date: 2023-03-27
Plan to share individual participant data: NO
Clinical trial NCT04232839: A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body
Official title: Formulation Selection and Subsequent Optimization of Two Different Oral Formulations of BI 894416 in Healthy Male Subjects (Open-label, Randomised, Single-dose Study in Two Parts; Trial Part 1: Five-period Crossover Design With an Additional Sixth Period in a Fixed Sequence; Trial Part 2: Three-period Crossover Followed by a Two-period Crossover Design)
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to company decision.
Enrollment: 24.0 (ACTUAL)
Number of arms: 10.0
Start date: 2020-02-25
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Baseline population: Treated set (TS): This analysis set included all subjects who were randomised and received at least one dose of trial medication.
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: http://trials.boehringer-ingelheim.com/
Clinical trial NCT03412773: Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
Official title: RATIONALE-301: A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 674.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-28
Primary completion date: 2022-07-11
Completion date: 2023-12-14
Plan to share individual participant data: YES
Clinical trial NCT03933865: Acute Pain Management in Patients on Opioid Replacement Therapy
Official title: Acute Pain Management in Patients on Opioid Replacement Therapy
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The COVID-19 pandemic and recruitment difficulties prompted the investigators to terminate study early.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-31
Primary completion date: 2022-02-24
Completion date: 2022-02-24
Plan to share individual participant data: NO
Clinical trial NCT01799889: Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
Official title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision to discontinue development of entospletinib.
Enrollment: 326.0 (ACTUAL)
Number of arms: 12.0
Start date: 2013-03-14
Primary completion date: 2017-09-14
Completion date: 2020-01-30
Baseline population: The Full Analysis Set included all enrolled participants who took at least one dose of study drug with treatment group designated according to the planned treatment.
Limitations and caveats: Study was terminated prematurely due to sponsor's decision to discontinue development of entospletinib.
Plan to share individual participant data: NO
Clinical trial NCT02867761: RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
Official title: RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
Acronym: RETHINC
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 780.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-29
Primary completion date: 2021-07-07
Completion date: 2021-07-07
Clinical trial NCT05006885: ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
Official title: A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease
Sponsor: Altimmune, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 95.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-30
Primary completion date: 2022-08-17
Completion date: 2022-08-17
Clinical trial NCT04638491: Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Official title: Phase 1, Single-arm, Open-label, Dose Escalating and Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of Lurbinectedin (PM01183) for Injection in Patients With Advanced Solid Tumors
Sponsor: Luye Pharma Group Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-24
Primary completion date: 2023-11-04
Completion date: 2023-11-04
Plan to share individual participant data: NO
Clinical trial NCT02298595: Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Official title: A Phase I/II Study of BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-08-31
Primary completion date: 2019-08-31
Completion date: 2024-08-31
Clinical trial NCT03499795: VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Official title: A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Sponsor: Inovio Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-15
Primary completion date: 2020-06-16
Completion date: 2021-05-26
Baseline population: mITT population included all participants who received at least 1 dose of VGX-3100+EP.
Plan to share individual participant data: NO
Clinical trial NCT03187769: Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
Official title: A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness
Sponsor: Alkermes, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 426.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-08
Primary completion date: 2021-12-01
Completion date: 2022-01-03
Baseline population: The baseline analysis population includes all randomized subjects who received at least 1 dose of study drug
Plan to share individual participant data: NO
Clinical trial NCT01849874: A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Official title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Per recommendation of the DMC, enrollment into the study was discontinued in April 2016 after the planned interim efficacy analysis showed the hazard ratio for PFS crossed the predefined futility boundary.
Enrollment: 341.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-06-27
Primary completion date: 2016-01-20
Completion date: 2022-08-23
Baseline population: Baseline analysis population included all participants in the safety population. Safety population consisted of all participants who received at any dose of study intervention (MEK162 or physician's choice chemotherapy).
Limitations and caveats: In the futility analysis based on PCD, the futility boundary was crossed, and therefore, no additional efficacy data was collected and no additional efficacy analyses were conducted. As of 01 Apr 2016, enrollment into the study were discontinued and crossover treatment was no longer permitted, any participants still receiving MEK162 were allowed to continue at the discretion of the investigator until any treatment discontinuation criterion was met and discontinued after 30-day safety follow up.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03527264: BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
Official title: BrUOG 355: A Pilot Feasibility Study Incorporating Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 4.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-11-08
Primary completion date: 2020-11-13
Completion date: 2020-11-13
Baseline population: Study was terminated prior to enrolling patients in cohort 2 \& cohort 3.
Plan to share individual participant data: NO
Clinical trial NCT03107793: Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Official title: Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Acronym: STARDUST
Sponsor: Janssen-Cilag Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 500.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-04-19
Primary completion date: 2020-04-30
Completion date: 2021-07-20
Clinical trial NCT04082000: Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy
Official title: A Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 Sublingual Drops for Treating Diabetic Neuropathy
Sponsor: Breath of Life International Pharma Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: study stopped due to company strategic prioritization
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-15
Primary completion date: 2020-11-04
Completion date: 2020-11-04
Clinical trial NCT00896493: Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Official title: A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 1.0
Start date: 2009-05-31
Primary completion date: 2021-11-06
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT04121143: A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults
Official title: Multicenter, Placebo-controlled, Parallel-randomized, Double-blind, Phase II Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of SHR-1314 Injection With Moderate to Severe Plaque Psoriasis in Adults
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: sponsor's decision
Enrollment: 120.0 (ESTIMATED)
Number of arms: 4.0
Start date: 2019-11-09
Primary completion date: 2020-06-30
Completion date: 2020-12-30
Plan to share individual participant data: NO
Clinical trial NCT05166876: Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
Official title: A Phase II, Randomized, Assessor-blind, Multicenter, Multi-dose, Placebo-controlled Study Assessing the Safety and Anti-coronavirus Response of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.
Acronym: CCBCRISIS04
Sponsor: Clear Creek Bio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low prevalence of COVID-19 in India led to lack of eligible subjects.
Enrollment: 26.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-02-01
Primary completion date: 2022-06-04
Completion date: 2022-06-04
Clinical trial NCT04786600: A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
Official title: A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slow accrual
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-14
Primary completion date: 2024-03-19
Completion date: 2024-03-19
Clinical trial NCT03539731: [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
Official title: A Phase I Study of [18F]DASA-23 as a PET Tracer for Evaluating Pyruvate Kinase M2 (PKM2) Expression in Healthy Volunteers and in Patients With Intracranial Tumors
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: study did not meet its objectives due to difficulties in enrollment
Enrollment: 27.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-04-23
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Clinical trial NCT04035317: Aesculus Hippocastanum L. on Fontan Circulation
Official title: Effect of Aesculus Hippocastanum L. (Sapindaceae, Horse Chestnut) on Fontan Circulation - a Randomized Clinical Trial
Sponsor: Casa Espirita Terra de Ismael (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The graduate student quit.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT05554627: VA Aripiprazole vs Esketamine for Treatment Resistant Depression
Official title: VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D II
Acronym: VAST-D II
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study funding was withdrawn by study sponsor (CSR\&D) prior to enrollment due to budget constraints.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-10-27
Primary completion date: 2023-10-27
Completion date: 2023-10-27
Plan to share individual participant data: NO